# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.
Bionomics' Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, c...